Business Description
Alto Neuroscience Inc
NAICS : 541713
SIC : 2836
ISIN : US02157Q1094
Total Employee Number:
68Description
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.36 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.33 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 0.4 | |||||
3-Year EPS without NRI Growth Rate | -0.9 | |||||
3-Year FCF Growth Rate | -3.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -13.44 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 92.35 | |||||
9-Day RSI | 80.56 | |||||
14-Day RSI | 71.33 | |||||
3-1 Month Momentum % | 1.15 | |||||
6-1 Month Momentum % | 14.27 | |||||
12-1 Month Momentum % | 815.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 20.52 | |||||
Quick Ratio | 20.52 | |||||
Cash Ratio | 20.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.7 | |||||
Shareholder Yield % | -12.97 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -48.34 | |||||
ROA % | -39.62 | |||||
ROIC % | -841.76 | |||||
3-Year ROIIC % | -573.03 | |||||
ROC (Joel Greenblatt) % | -1082.68 | |||||
ROCE % | -40.44 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.89 | |||||
Price-to-Tangible-Book | 3.9 | |||||
EV-to-EBIT | -9.85 | |||||
EV-to-EBITDA | -9.95 | |||||
EV-to-Forward-EBITDA | -6.73 | |||||
EV-to-FCF | -11.27 | |||||
| Price-to-Net-Current-Asset-Value | 4.01 | |||||
| Price-to-Net-Cash | 4.1 | |||||
Earnings Yield (Greenblatt) % | -10.15 | |||||
FCF Yield % | -6.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:ANRO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alto Neuroscience Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.42 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 252.49 | ||
| 14-Day RSI | 71.33 | ||
| 14-Day ATR ($) | 1.777964 | ||
| 20-Day SMA ($) | 21.4505 | ||
| 12-1 Month Momentum % | 815.65 | ||
| 52-Week Range ($) | 2.15 - 28.441 | ||
| Shares Outstanding (Mil) | 35.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alto Neuroscience Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alto Neuroscience Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 137 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 46 days | ||
| Jefferies Global Healthcare Conference | 2026-06-03 09:20 | 18.71 (-4.20%) | ||
| Bank of America Securities Healthcare Conference | 2026-05-13 17:15 | 24.63 (+0.12%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 24.63 (+0.12%) | ||
| General meeting for 2026 | 2026-05-12 08:30 | 24.53 (+0.78%) | ||
| Guidance call for 2026 | 2026-03-17 12:00 | 24.29 (+8.92%) | ||
| Annual report for 2025 | 2026-03-16 | 22.26 (-1.07%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 22.26 (-1.07%) | ||
| TD Cowen 46th Annual Healthcare Conference | 2026-03-03 13:50 | 20.63 (+6.61%) |
Show
Entries
Alto Neuroscience Inc Frequently Asked Questions
What is Alto Neuroscience Inc(ANRO)'s stock price today?
The current price of ANRO is $27.04. The 52 week high of ANRO is $28.44 and 52 week low is $2.15.
When is next earnings date of Alto Neuroscience Inc(ANRO)?
The next earnings date of Alto Neuroscience Inc(ANRO) is 2026-08-13 Est..
Does Alto Neuroscience Inc(ANRO) pay dividends? If so, how much?
Alto Neuroscience Inc(ANRO) does not pay dividend.
Guru Commentaries on NYSE:ANRO
No articles.
Press Release
Articles on Alto Neuroscience Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers